Regression of Cervical Precancerous Lesions and Associated Risk Factors

Recruiting now

Conditions studied: Cervix Uteri SIL, HPV, CIN2, CIN3

In brief

The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.

Key facts

Study ID

NCT06147388

Run by

General University Hospital, Prague

People needed

300

Starts

2022-09-01

Expected to finish

2027-07-01

Last updated by the study team

2026-02-25

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• squamocolumnar junction fully visualized
• bioptically verified CIN 2 or CIN 3
• age ≥ 18 years
• age ≤ 40 years
• informed consent

You may not qualify if…

• squamocolumnar junction not fully visualized
• suspicion on glandular lesion
• suspicion on invasive cancer
• personal history of CIN 2, 3 or cerv. cancer
• gravidity
• HIV positivity
• immunosuppression
• impossible photographic documentation

Where it is running

• General University Hospital — Prague, Czechia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.